Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.88
- Piotroski Score 4.00
- Grade Buy
- Symbol (IMAB)
- Company I-Mab
- Price $1.08
- Changes Percentage (-0.77%)
- Change -$0.01
- Day Low $1.07
- Day High $1.10
- Year High $2.54
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.48
- Trailing P/E Ratio -0.76
- Forward P/E Ratio -0.76
- P/E Growth -0.76
- Net Income $-1,465,694,000
Income Statement
Quarterly
Annual
Latest News of IMAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Otsuka's sibeprenlimab shows promise in Phase III IgA nephropathy trial
Otsuka Pharmaceutical's Phase III trial on sibeprenlimab for IgA nephropathy showed positive interim results. The monoclonal antibody demonstrated a significant reduction in urine protein levels, meet...
By Yahoo! Finance | 1 week ago -
GSK's depemokimab shows promise in Phase III trials for chronic rhinosinusitis
GSK's Phase III trials of depemokimab in CRSwNP patients showed significant improvements compared to placebo, meeting primary endpoints. The drug's potential as a convenient treatment option is promis...
By Yahoo! Finance | 3 weeks ago -
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK plc announced positive results from phase 3 trials for depemokimab in treating chronic rhinosinusitis with nasal polyps. The trials met primary endpoints, showing efficacy and safety in reducing p...
By Yahoo! Finance | 3 weeks ago
